Analyst Reports

The analyst research linked below is commissioned and paid for by ExpreS2ion Biotech Holding AB to support market understanding of the company. Reports are currently produced by Redeye and H.C. Andersen Capital, and were previously produced by Analysguiden (Aktiespararna) and Pareto Securities, under agreements with ExpreS2ion. These reports are prepared independently by the respective research providers, who retain full editorial control over their analyses and conclusions.

ExpreS2ion may review factual information for accuracy before publication but does not influence the analysts’ views, assumptions, or investment conclusions. Because the research is commissioned, investors should be aware of the potential for conflicts of interest.

The reports are provided for informational purposes only and do not constitute investment advice, recommendations, or an offer to buy or sell financial instruments. Investors should always base investment decisions on ExpreS2ion’s official disclosures, regulatory filings, and their own assessment.

English reports

Analysguiden

22 August 2024 | Analysguiden - At the gates of Phase I

23 May 2024 | Analysguiden - Improving cash position

15 February 2024 | Analysguiden - Breast cancer on stage

27 Nov 2023 | Analysguiden - New strategy evolving

15 Mar 2023 | Analysguiden - Ever-changing landscape

18 Nov 2022 | Analysguiden - Promising long-term data

13 Jun 2022 | Analyseguiden - Preparing for the final

8 Mar 2022 | Analysguiden - A moving target

9 Dec 2021 | Analysguiden - Solid data open for final phase

19 Nov 2021 | Analysguiden - Phase 2 data pending

23 Aug 2021 | Analysguiden - Funding still pending

22 Apr 2021 | Analysguiden - First human data reassuring

27 Jan 2021 | Analysguiden - Getting Close To Patients

3 Sep 2020 | Analysguiden - Broadening the Portfolio

21 Nov 2019 | Analysguiden - Potential at Reduced Risk

Pareto Securities

17 October 2024 Pareto | SIIPL Term Sheet

15 August 2024 Pareto | 2024 Second Quarter Results

11 July 2024 Pareto | 2024 Rights Issue results

16 May 2024 Pareto | 2024 First Quarter Results

3 May 2024 Pareto | 2024 Rights Issue

23 April 2024 Pareto | AdaptVac Dividend

16 April 2024 Pareto | Completion of pre-clinical safety

22 February 2024 Pareto | ABNCoV2 milestone payment

8 February 2024 Pareto | 2023 YE Report (Newsflash)

4 December 2023 Pareto | Pipeline addition - Nipah

4 December 2023 Pareto | Spotlight: Cancer vaccine ES2B-C001

17 August 2023 | Pareto - Evaluating BC strategic options (Newsflash)

27 June 2023 Pareto | ABNCoV2 phase II meets primary endpoint (Newsflash)

16 June 2023 Pareto | ABNCoV2 strong durability data (Newsflash)

16 May 2023 Pareto | 2023 Q1 Report (Newsflash)

18 April 2023 Pareto | Initial gross proceeds of SEK 54.5m

6 March 2023 Pareto | 2023 Right Issue Announcement

3 March 2023 Pareto | Mucosal Vaccine

9 February 2023 Pareto | 2022 YE Report Newsflash

6 December 2022 Pareto | Evaxion CMV vaccine collaboration Newsflash

17 November 2022 Pareto | 9M 2022 Report Newsflash

24 Oct 2022 Pareto | ES2B-C001 positive preclinical data published

18 Oct 2022 Pareto | ABNCoV2 reports positive phase II durability data

22 Sep 2022 Pareto | COVID vaccine phase III trial ongoing

8 Apr 2022 Pareto | Cash position to be further increased

1 Mar 2022 Pareto | Further progress with COVID-19 vaccine

10 Jan 2022 Pareto | Exciting topline preclinical results for ES2B-C001

7 Dec 2021 | Pareto - Great ABNCoV2 Phase II top line results

17 Nov 2021 | Pareto - COVID-19 vaccine Phase II readout on the horizon

20 Aug 2021 | Pareto - Initiation of Phase II trial just around the corner

9 Aug 2021 | Pareto - Great COUGH-1 headline results

24 Jun 2021 | Pareto - Rights to COVID-19 Challenge (Initiation)